Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens

Mark Lawler; Peter Naredi; Tanja Cufer; Ian Banks; Yolande Lievens; Giles Vassal; Matti Aapro; Maja Južnič Sotlar; Thierry Philip; Jacek Jassem; Jana Pelouchova; Françoise Meunier; Richard Sullivan

doi:10.1016/S1470-2045(19)30648-5

Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens

Mark Lawler, Peter Naredi, Tanja Cufer, Ian Banks, Yolande Lievens, Giles Vassal, Matti Aapro, Maja Južnič Sotlar, Thierry Philip, Jacek Jassem, Jana Pelouchova, Françoise Meunier, Richard Sullivan

Résultats de recherche: Contribution à un journal › !!Comment/debate

3 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1482-1485
Nombre de pages	4
journal	The Lancet Oncology
Volume	20
Numéro de publication	11
Les DOIs	https://doi.org/10.1016/S1470-2045(19)30648-5
état	Publié - 1 nov. 2019

Accès au document

10.1016/S1470-2045(19)30648-5

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d6f4de4b47994420821736de78b3b9a5,

title = "Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens",

author = "Mark Lawler and Peter Naredi and Tanja Cufer and Ian Banks and Yolande Lievens and Giles Vassal and Matti Aapro and Sotlar, {Maja Ju{\v z}ni{\v c}} and Thierry Philip and Jacek Jassem and Jana Pelouchova and Fran{\c c}oise Meunier and Richard Sullivan",

note = "Funding Information: ML reports an unrestricted educational grant from Pfizer, honoraria from Pfizer and EMD Serono, and is a board member of the European Alliance for Personalised Medicine (EAPM). TC reports honoraria for lectures and advisory board consulations from AstraZeneca, Roche, Pfizer, Merck Sharp&Dohme, Bristol Myers Squibb, and Boehringer Ingelheim. YL reports honoraria for advisory board consultations from AstraZeneca and for lectures from RaySearch. MJS reports honoraria for advisory board consultations from Pfizer and Servier. MA reports grant/research support from Amgen, Eisai, Genomic Health, Helsinn, Hospira, Novartis, Merck, Mundipharma, Pfizer, Roche, Sandoz, Tesaro, Teva, and Vifor; is/was a consultant for Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, G1, GlaxoSmithKline, Helsinn, Hospira, J&J, Novartis, Merck, Merck Serono, Mundipharma, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Teva, and Vifor; has received honoraria for lectures at symposia (equivalent speaker's bureau) of Amgen, Bayer Schering, Cephalon, Chugai, Eisai, Genomic Health, GlaxoSmithKline, Helsinn, Hospira, Ipsen, JnJ OrthoBiotech, Kyowa Hakko Kirin, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Teva, and Vifor; and is on the Board of ESO, SPCC, and SIOG and is president-elect of ECCO. JJ reports honoraria from AstraZeneca, BMS, Merck, Pfizer, Roche, Abbvie, and Eisai, and travel support from Pfizer and Roche. RS reports an unrestricted educational grant from Pfizer. IB, PN, TP, GV, JP, and FM declare no competing interests.",

year = "2019",

month = nov,

day = "1",

doi = "10.1016/S1470-2045(19)30648-5",

language = "English",

volume = "20",

pages = "1482--1485",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "11",

}

TY - JOUR

T1 - Moonshot or groundshot

T2 - addressing Europe's cancer challenge through a patient-focused, data-enabled lens

AU - Lawler, Mark

AU - Naredi, Peter

AU - Cufer, Tanja

AU - Banks, Ian

AU - Lievens, Yolande

AU - Vassal, Giles

AU - Aapro, Matti

AU - Sotlar, Maja Južnič

AU - Philip, Thierry

AU - Jassem, Jacek

AU - Pelouchova, Jana

AU - Meunier, Françoise

AU - Sullivan, Richard

N1 - Funding Information: ML reports an unrestricted educational grant from Pfizer, honoraria from Pfizer and EMD Serono, and is a board member of the European Alliance for Personalised Medicine (EAPM). TC reports honoraria for lectures and advisory board consulations from AstraZeneca, Roche, Pfizer, Merck Sharp&Dohme, Bristol Myers Squibb, and Boehringer Ingelheim. YL reports honoraria for advisory board consultations from AstraZeneca and for lectures from RaySearch. MJS reports honoraria for advisory board consultations from Pfizer and Servier. MA reports grant/research support from Amgen, Eisai, Genomic Health, Helsinn, Hospira, Novartis, Merck, Mundipharma, Pfizer, Roche, Sandoz, Tesaro, Teva, and Vifor; is/was a consultant for Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, G1, GlaxoSmithKline, Helsinn, Hospira, J&J, Novartis, Merck, Merck Serono, Mundipharma, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Teva, and Vifor; has received honoraria for lectures at symposia (equivalent speaker's bureau) of Amgen, Bayer Schering, Cephalon, Chugai, Eisai, Genomic Health, GlaxoSmithKline, Helsinn, Hospira, Ipsen, JnJ OrthoBiotech, Kyowa Hakko Kirin, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Teva, and Vifor; and is on the Board of ESO, SPCC, and SIOG and is president-elect of ECCO. JJ reports honoraria from AstraZeneca, BMS, Merck, Pfizer, Roche, Abbvie, and Eisai, and travel support from Pfizer and Roche. RS reports an unrestricted educational grant from Pfizer. IB, PN, TP, GV, JP, and FM declare no competing interests.

PY - 2019/11/1

Y1 - 2019/11/1

UR - http://www.scopus.com/inward/record.url?scp=85074108344&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30648-5

DO - 10.1016/S1470-2045(19)30648-5

M3 - Comment/debate

C2 - 31674308

AN - SCOPUS:85074108344

SN - 1470-2045

VL - 20

SP - 1482

EP - 1485

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -